8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Oct 30, 2020)

Filed October 30, 2020For Securities:PFE

Summary

Pfizer Inc. has announced a significant step towards the completion of its previously announced separation of its Upjohn business, which primarily consists of off-patent branded and generic established medicines. On October 30, 2020, the company issued a press release confirming the receipt of all necessary antitrust approvals. This clearance is a critical milestone, paving the way for the anticipated closing of the spin-off transaction. Following the spin-off, the Upjohn business is set to combine with Mylan N.V. This strategic move is designed to unlock value by creating two more focused companies: one centered on innovative medicines and the other on established medicines. Investors should monitor the official closing date for this transaction, as it will mark the formal separation of these distinct business segments and the formation of the new combined entity with Mylan.

Key Highlights

  • 1Pfizer received all required antitrust approvals for the spin-off of its Upjohn business.
  • 2The Upjohn business will be spun off and subsequently combined with Mylan N.V.
  • 3This transaction represents a strategic move to create two more focused companies.
  • 4The press release announcing these approvals was issued on October 30, 2020.
  • 5Antitrust clearance is a key prerequisite for the transaction's closing.

Frequently Asked Questions

This 8-K filing primarily announces that Pfizer has received all necessary antitrust approvals for the spin-off of its Upjohn business and its subsequent combination with Mylan N.V.

The Upjohn business is Pfizer's global division focused on primarily off-patent branded and generic established medicines.

Receiving antitrust approvals is a critical step that allows the transaction to proceed towards its anticipated closing. It signifies that regulatory bodies have reviewed the deal and found no significant competitive concerns.

While the press release confirms receipt of approvals, the filing does not specify an exact closing date, referring to it as the 'anticipated closing'. Investors should look for future announcements regarding the official closing date.